1.
Paul R. The Threat of Multidrug-resistant Tuberculosis. J Glob Infect Dis. 2018;10(3):119–20.
2.
World Health Organization (WHO). WHO | Global tuberculosis report 2018. WHO [Internet].
2019 [cited 2019 May 2]; Available from: https://www.who.int/tb/publications/global_report/en/
5.
Avong YK, Isaakidis P, Hinderaker SG, Van Den Bergh R, Ali E, Obembe BO, et al. Doing
no harm? Adverse events in a nation-wide cohort of patients with multidrug-resistant
tuberculosis in Nigeria. PLoS One. 2015 Mar 17;10(3):1–15.
6.
Patel S V., Nimavat KB, Alpesh PB, Shukla LK, Shringarpure KS, Mehta KG, et al. Treatment
outcome among cases of multidrug-resistant tuberculosis (MDR TB) in Western India:
A prospective study. J Infect Public Health. 2016 Jul 1;9(4):478–84.
7.
Vashrambhai Patel S, Kapil Bhikhubhai N, Bhimabhai patel A, Samrat Shringarpure K,
Gautambhai Mehta K, Krishnakumar Shukla L, et al. Adverse Drug Reactions in Patients
put on Multi Drug Resistant Tuberculosis (MDR-TB) Treatment in Seven Districts of
Central Gujarat. J Young Pharm. 7.
8.
Hoa NB, Nhung NV, Khanh PH, Hai NV, Quyen BTT. Adverse events in the treatment of
MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh
City, Vietnam. BMC Res Notes. 2015;8(1):4–9.
9.
Patil S, Bhagwat R, Mohite R, Barphe S. Profile of adverse drug reactions in multiple
drug resistant tuberculosis patients at drug resistant-tuberculosis center - Miraj,
Maharashtra. Int J Med Sci Public Heal. 2016;6(4):1.
10.
Suryawanshi SL, Shewade HD, Nagaraja SB, Nair SA, Parmar M. Unfavourable outcomes
among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India.
Public Heal Action. 2017;7(2):116–22.
11.
Sengul A, Akturk UA, Aydemir Y, Kaya N, Kocak ND, Tasolar FT. Factors affecting successful
treatment outcomes in pulmonary tuberculosis: A single-center experience in Turkey,
2005-2011. J Infect Dev Ctries. 2015;9(8):821–8.
12.
Sadiq S, Khajuria V, Tandon VR, Mahajan A, Singh JB. Adverse drug reaction profile
in patients on anti-tubercular treatment alone and in combination with highly active
antiretroviral therapy. J Clin Diagnostic Res. 2015;9(10):FC01–4.
13.
Tag El Din MA, El Maraghy AA, Abdel Hay AHR. Adverse reactions among patients being
treated for multi-drug resistant tuberculosis at Abbassia Chest Hospital. Egypt J
Chest Dis Tuberc [Internet]. 2015;64(4):939–52. Available from: http://dx.doi.org/10.1016/j.ejcdt.2015.03.004
14.
Rathod KB, Borkar MS, Lamb AR, Suryavanshi SL, Surwade GA, Pandey VR. Adverse events
among patients of multi drug resistant tuberculosis receiving second line anti TB
treatment. Int J Sci Reports. 2015;1(6):253.
15.
Kapadia VK, Tripathi SB. Adverse drug reactions and outcome analysis of MDR TB patients
on DOTS plus regimen. Natl J Community Med. 2016;7(1):5–9.
19.
KoBoToolbox | Data Collection Tools for Challenging Environments [Internet]. [cited
2019 May 21]. Available from: https://www.kobotoolbox.org/
21.
Isaakidis P, Varghese B, Mansoor H, Cox HS, Ladomirska J, Saranchuk P, et al. Adverse
events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line
anti-TB treatment in Mumbai, India. PLoS One. 2012;7(7).
22.
STROBE Statement-checklist of items that should be included in reports of observational
studies [Internet]. [cited 2019 May 2]. Available from: http://www.epidem.com/
24.
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research
(COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Heal Care.
2007 Sep 16;19(6):349–57.
25.
Lv X, Tang S, Xia Y, Wang X, Yuan Y, Hu D, et al. Adverse Reactions Due to Directly
Observed Treatment Strategy Therapy in Chinese Tuberculosis Patients: A Prospective
Study. PLoS One. 2013;8(6):1–8.
26.
Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas A, Kumar AMV, Satyanarayana S, et al.
Patient and provider reported reasons for lost to follow up in MDRTB treatment: A
qualitative study from a drug resistant TB Centre in India. PLoS One. 2015;10(8):1–11.
27.
Shringarpure KS, Isaakidis P, Sagili KD, Baxi RK, Das M, Daftary A. “When treatment
is more challenging than the disease”: A qualitative study of MDR-TB patient retention.
PLoS One. 2016;11(3):1–12.
28.
Kelly, AM; Smith B. Discordance between patient and clinician report of MDR-TB adverse
drug reaction. Int J Tuberc Lung Dis. 2016;20(4):442–7.
29.
Allen EN, Mushi AK, Massawe IS, Vestergaard LS, Lemnge M, Staedke SG, et al. How experiences
become data: the process of eliciting adverse event, medical history and concomitant
medication reports in antimalarial and antiretroviral interaction trials. BMC Med
Res Methodol. 2013 Dec 14;13(1):140.
30.
Corser W, Sikorskii A, Olomu A, Stommel M, Proden C, Holmes-Rovner M. "Concordance
between comorbidity data from patient self-report interviews and medical record documentation"
BMC Health Serv Res. 2008 Dec 16;8(1):85.
31.
Pakhomov S V, Jacobsen SJ, Chute CG, Roger VL. Agreement between patient-reported
symptoms and their documentation in the medical record. Am J Manag Care. 2008 Aug;14(8):530–9.
32.
Ani C, Bazargan M, Hindman D, Bell D, Farooq MA, Akhanjee L, et al. Depression symptomatology
and diagnosis: discordance between patients and physicians in primary care settings.
BMC Fam Pract. 2008 Dec 3;9(1):1.
33.
Bhardwaj P, Deshkar AM, Verma R. Side Effects Encountered in Treatment of Multidrug-resistant
Tuberculosis: A 3-Year Experience at First Dots Plus Site of Chhattisgarh. Int J Sci
Study. 2015;3(5):104–7.
34.
Vashrambhai Patel S, Kapil Bhikhubhai N, Bhimabhai patel A, Samrat Shringarpure K,
Gautambhai Mehta K, Krishnakumar Shukla L. Adverse Drug Reactions in Patients put
on Multi Drug Resistant Tuberculosis (MDR-TB) Treatment in Seven Districts of Central
Gujarat. J Young Pharm. 2015;7(4s):425–31.
35.
Berger SI, Iyengar R. Role of systems pharmacology in understanding drug adverse events.
Wiley Interdiscip Rev Syst Biol Med. 2011;3(2):129–35.
36.
World Health Organization (WHO). WHO | Pharmacovigilance [Internet]. WHO. World Health
Organization; 2015 [cited 2019 Apr 30]. Available from: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/
37.
Hire R, Kale AS, Dakhale GN, Gaikwad N. A prospective, observational study of adverse
reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central
India. Mediterr J Hematol Infect Dis. 2014;6(1).
38.
Khan S, Goyal C, Chandel N, Rafi M. Knowledge, attitudes, and practice of doctors
to adverse drug reaction reporting in a teaching hospital in India: An observational
study. J Nat Sci Biol Med. 2013 Jan;4(1):191.
39.
Jose J, Jimmy B, Al-Ghailani ASH, Al Majali MA. A cross sectional pilot study on assessing
the knowledge, attitude and behavior of community pharmacists to adverse drug reaction
related aspects in the Sultanate of Oman. Saudi Pharm J. 2014 Apr;22(2):163–9.
40.
Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM. Attitudinal survey of adverse drug
reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol.
1995 Mar;39(3):223–6.
41.
Jose J, Jimmy B, Al-Mamari MNS, Al-Hadrami TSN, Al-Zadjali HM. Knowledge, Beliefs
and Behaviours Regarding the Adverse Effects of Medicines in an Omani Population:
Cross-sectional survey. Sultan Qaboos Univ Med J. 2015 May;15(2):250–6.
42.
Babu R, Soundappan K, Anand T, Chadha S. Challenges in management of tuberculosis
under programmatic conditions:Perceptions of health care providers from four states
of India. Indian J Community Heal. 2017;29.
43.
Fuady A, Houweling TAJ, Mansyur M, Richardus JH. Catastrophic total costs in tuberculosis-affected
households and their determinants since Indonesia’s implementation of universal health
coverage. Infect Dis Poverty. 2018 Dec 12;7(1):3.
44.
De-Loyde KJ, Harrison JD, Durcinoska I, Shepherd HL, Solomon MJ, Young JM. Which information
source is best? Concordance between patient report, clinician report and medical records
of patient co-morbidity and adjuvant therapy health information. J Eval Clin Pract.
2015;21(2):339–46.